(Q33843993)

29 July 2017

1 reference

title

Beta-interferon for multiple sclerosis (English)

1 reference

29 July 2017

0 references

Richard A Rudick

1

1 reference

29 July 2017

Susan E Goelz

series ordinal

2

1 reference

29 July 2017

language of work or name

English

0 references

publication date

21 March 2011

1 reference

Experimental Cell Research

29 July 2017

published in

1 reference

29 July 2017

volume

317

1 reference

29 July 2017

issue

9

1 reference

29 July 2017

page(s)

1301-1311

1 reference

Intrathecal Interferon Reduces Exacerbations of Multiple Sclerosis

29 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.03.002

Clinical trial of natural alpha interferon in multiple sclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.03.002

Multicentre double-blind study of effect of intrathecally administered natural human fibroblast interferon on exacerbations of multiple sclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.03.002

Interferon-alpha and transfer factor in the treatment of multiple sclerosis: a double-blind, placebo-controlled trial. AUSTIMS Research Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.03.002

Systemic lymphoblastoid interferon therapy in chronic progressive multiple sclerosis. I. Clinical and MRI evaluation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.03.002

Exacerbations of multiple sclerosis in patients treated with gamma interferon

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.03.002

Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.03.002

Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.03.002

Use of the brain parenchymal fraction to measure whole brain atrophy in relapsing-remitting MS. Multiple Sclerosis Collaborative Research Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.03.002

Use of the multiple sclerosis functional composite as an outcome measure in a phase 3 clinical trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.03.002

Interferon beta-1b in secondary progressive MS: a combined analysis of the two trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.03.002

Interferon beta-1a in primary progressive MS: an exploratory, randomized, controlled trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.03.002

Estimating long-term effects of disease-modifying drug therapy in multiple sclerosis patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.03.002

Analysis of clinical outcomes according to original treatment groups 16 years after the pivotal IFNB-1b trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.03.002

PRISMS-4: Long-term efficacy of interferon-beta-1a in relapsing MS.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.03.002

Long-term subcutaneous interferon beta-1a therapy in patients with relapsing-remitting MS.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.03.002

Interferons: biochemistry and mechanisms of action

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.03.002

Actions of cytokines on the immune response and viral interactions: an overview

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.03.002

Complex modulation of cell type-specific signaling in response to type I interferons

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.03.002

The interferon-alpha/beta system in antiviral responses: a multimodal machinery of gene regulation by the IRF family of transcription factors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.03.002

Pharmacokinetics and biologic activities of human native and asialointerferon-beta s

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.03.002

Structural and functional differences between glycosylated and non-glycosylated forms of human interferon-beta (IFN-beta).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.03.002

Characterization of a soluble ternary complex formed between human interferon-beta-1a and its receptor chains

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.03.002

The receptor of the type I interferon family

7 January 2021

2 references

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.03.002

7 January 2021

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.03.002

inferred from DOI database lookup

7 January 2021

based on heuristic

Structure-function study of the extracellular domain of the human type I interferon receptor (IFNAR)-1 subunit

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.03.002

Configuration of the interferon-alpha/beta receptor complex determines the context of the biological response

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.03.002

Alternative and accessory pathways in the regulation of IFN-beta-mediated gene expression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.03.002

How cells respond to interferons

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.03.002

Role of the cytoplasmic domains of the type I interferon receptor subunits in signaling

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.03.002

Interferon-beta induces the development of type 2 dendritic cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.03.002

Regulation of differentiation and functional properties of monocytes and monocyte-derived dendritic cells by interferon beta in multiple sclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.03.002

Interferon-beta-1a treatment increases CD56bright natural killer cells and CD4+CD25+ Foxp3 expression in subjects with multiple sclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.03.002

Identification of short-term pharmacodynamic effects of interferon-beta-1a in multiple sclerosis subjects with broad- based phenotypic profiling.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.03.002

A randomized, double-blind, dose-comparison study of weekly interferon beta-1a in relapsing MS

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.03.002

250 microg or 500 microg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.03.002

PEGylated interferon beta-1a: meeting an unmet medical need in the treatment of relapsing multiple sclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.03.002

Bioequivalence and the immunogenicity of biopharmaceuticals

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.03.002

Measuring and management of anti-interferon beta antibodies in subjects with multiple sclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.03.002

Neutralizing antibodies to interferon-beta and other immunological treatments for multiple sclerosis: prevalence and impact on outcomes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.03.002

Persistent neutralizing antibodies abolish the interferon beta bioavailability in MS patients.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.03.002

Neutralizing antibodies during treatment of multiple sclerosis with interferon beta-1b: experience during the first three years. The IFNB Multiple Sclerosis Study Group and the University of British Columbia MS/MRI Analysis Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.03.002

Interferon beta-1a in MS: results following development of neutralizing antibodies in PRISMS

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.03.002

Absence of MxA induction by interferon beta in patients with MS reflects complete loss of bioactivity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.03.002

Effect of neutralizing antibodies on biomarker responses to interferon beta: the INSIGHT study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.03.002

Incidence and significance of neutralizing antibodies to interferon beta-1a in multiple sclerosis. Multiple Sclerosis Collaborative Research Group (MSCRG)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.03.002

Appearance and disappearance of neutralizing antibodies during interferon-beta therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.03.002

Persistence of neutralizing antibodies after discontinuation of IFNbeta therapy in patients with relapsing-remitting multiple sclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.03.002

Monthly corticosteroids decrease neutralizing antibodies to IFNbeta1 b: a randomized trial in multiple sclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.03.002

Clinical effect of neutralizing antibodies to interferon beta that persist long after cessation of therapy for multiple sclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.03.002

Disease protection and interleukin-10 induction by endogenous interferon-β in multiple sclerosis?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.03.002

Malignant melanoma in a multiple sclerosis patient with persistent neutralizing antibodies to interferon-beta

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.03.002

HLA-DRB1*0401 and HLA-DRB1*0408 are strongly associated with the development of antibodies against interferon-beta therapy in multiple sclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.03.002

Guidelines on use of anti-IFN-beta antibody measurements in multiple sclerosis: report of an EFNS Task Force on IFN-beta antibodies in multiple sclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.03.002

Neutralizing antibodies to interferon beta: assessment of their clinical and radiographic impact: an evidence report: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.03.002

Recommendations for clinical use of data on neutralising antibodies to interferon-beta therapy in multiple sclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.03.002

Genomic effects of IFN-beta in multiple sclerosis patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.03.002

Breakthrough disease during interferon-[beta] therapy in MS: No signs of impaired biologic response

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.03.002

IFN-beta1b induces transient and variable gene expression in relapsing-remitting multiple sclerosis patients independent of neutralizing antibodies or changes in IFN receptor RNA expression.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.03.002

Gene expression analysis of interferon-beta treatment in multiple sclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.03.002

Time course transcriptomics of IFNB1b drug therapy in multiple sclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.03.002

Pharmacogenomics of interferon-beta therapy in multiple sclerosis: baseline IFN signature determines pharmacological differences between patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.03.002

Heterogeneous, longitudinally stable molecular signatures in response to interferon-beta

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.03.002

Cell-type specific gene expression signature in liver underlies response to interferon therapy in chronic hepatitis C infection.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.03.002

Urinary neopterin and nitric oxide metabolites as markers of interferon beta-1a activity in primary progressive multiple sclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.03.002

Interferon beta induces interleukin-10 expression: relevance to multiple sclerosis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.03.002

T helper type 1 and 17 cells determine efficacy of interferon-beta in multiple sclerosis and experimental encephalomyelitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.03.002

Alterations in serum MMP-8, MMP-9, IL-12p40 and IL-23 in multiple sclerosis patients treated with interferon-beta1b.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.03.002

Interferon-beta-1b increases serum interleukin-12 p40 levels in primary progressive multiple sclerosis patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.03.002

Increases in soluble VCAM-1 correlate with a decrease in MRI lesions in multiple sclerosis treated with interferon beta-1b.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.03.002

Defining interferon beta response status in multiple sclerosis patients.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.03.002

One-year MRI scan predicts clinical response to interferon beta in multiple sclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.03.002

A type I interferon signature in monocytes is associated with poor response to interferon-beta in multiple sclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.03.002

Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. UBC MS/MRI Study Group and the IFNB Multiple Sclerosis Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.03.002

Magnetic resonance studies of intramuscular interferon beta-1a for relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.03.002

Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.03.002

Magnetic resonance imaging results of the PRISMS trial: a randomized, double-blind, placebo-controlled study of interferon-beta1a in relapsing-remitting multiple sclerosis. Prevention of Relapses and Disability by Interferon-beta1a Subcutaneously in

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.03.002

Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.03.002

Evidence of interferon beta-1a dose response in relapsing-remitting MS: the OWIMS Study. The Once Weekly Interferon for MS Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.03.002

Effect of interferon-beta1b on magnetic resonance imaging outcomes in secondary progressive multiple sclerosis: results of a European multicenter, randomized, double-blind, placebo-controlled trial. European Study Group on Interferon-beta1b in secon

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.03.002

Interferon beta-1b in secondary progressive MS: results from a 3-year controlled study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.03.002

Randomized controlled trial of interferon- beta-1a in secondary progressive MS: Clinical results

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.03.002

Randomized controlled trial of interferon-beta-1a in secondary progressive MS: MRI results

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.03.002

Benefit of interferon beta-1a on MSFC progression in secondary progressive MS.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.03.002

Bioavailability of interferon beta 1b in MS patients with and without neutralizing antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.03.002

Serum IFN neutralizing antibodies and neopterin levels in a cross-section of MS patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.03.002

Neutralizing antibodies reduce MxA protein induction in interferon-beta-1a-treated MS patients.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.03.002

Differential effects of three interferon betas on neutralising antibodies in patients with multiple sclerosis: a follow up study in an independent laboratory.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.03.002

Neutralizing antibodies reduce the efficacy of betaIFN during treatment of multiple sclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.03.002

Longitudinal analyses of the effects of neutralizing antibodies on interferon beta-1b in relapsing-remitting multiple sclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.03.002

The clinical impact of interferon beta antibodies in relapsing-remitting MS.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.03.002

Neutralizing antibodies and efficacy of interferon beta-1a: a 4-year controlled study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.03.002

Clinical importance of neutralising antibodies against interferon beta in patients with relapsing-remitting multiple sclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2011.03.002

10.1016/J.YEXCR.2011.03.002

7 January 2021

Identifiers

DOI

1 reference

29 July 2017

1 reference